Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot-Assisted colonoscopy: a safer scope?

NCT ID NCT07606963

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study will test a new robotic device called the Triton 1.5 System for performing colonoscopies, which are exams to look for colon cancer. About 40 adults who need a routine colonoscopy will take part. The main goal is to see if the robot is safe and can successfully complete the exam.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 22 years 2. Adults indicated for elective screening, surveillance or diagnostic colonoscopy 3. Subject is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures 4. Subject is willing and able to comply with all protocol required preparation and follow- up visits Exclusion Criteria: 1. Any medical or physical condition/limitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator. 2. Any active or magnetic implantable medical devices (e.g., pacemakers, defibrillators) 3. Previous failed colonoscopy (except for inadequate bowel preparation) 4. BMI \> 45 kg/m2 5. Pregnant participants, women of reproductive potential (pre-menopausal and/or no history of hysterectomy), confirmed by a positive pregnancy test (serum). 6. Surgically altered colonic anatomy 7. History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon 8. Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day 9. Known bleeding tendency such as hemophilia or coagulation factor deficiencies 10. Subject receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin 11. Known colonic stricture 12. Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment 13. Known abdominal wall hernias 14. History of radiotherapy to the abdomen or pelvis 15. History of mesenteric ischemia 16. Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure 17. Contraindication to the proposed sedation / anesthesia 18. Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure 19. Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure 20. Participation in any concurrent clinical trial that may impact the results of this study Intra-Operative Criteria: 1. Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) (Appendix A) score \< 2 in any segment. 2. Any intraoperative finding or condition that, in the Investigator's judgment, would make study participation unsafe or not in the subject's best interest (e.g., significant stricture, tight sigmoid colon precluding safe overtube passage).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonoscopy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • HT Centrum Medyczne

    Tychy, Silesian Voivodeship, 43-100, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.